Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S ADR (NY: NVO )

105.06 +2.43 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Smitten With Novo Nordisk
Sorry to go on and on about Novo Nordisk, but this bearish position is by far my favorite right now. 
Via Talk Markets
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus. 
Via The Motley Fool
Benzinga Bulls And Bears: Nvidia, Tesla, MicroStrategy, Plug Power — And Crypto Traders Anticipate Dogecoin Topping 50 Cents
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA considers banning compounded versions. 
Via Benzinga
Exposures Product Safety
Hims & Hers Stock Dropped: Here's What You Need to Know
The GLP-1 drama continues at Hims & Hers. 
Via The Motley Fool
Behind the Scenes of Novo Nordisk's Latest Options Trends
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Analyst Ratings For Novo Nordisk
Via Benzinga
Monster and Celsius Energized: Which Stock Offers More Upside?
Energy drinks face negative publicity and competition, leading to sell-offs in Monster and Celsius. Increasing foot traffic may offer hope for a recovery. 
Via MarketBeat
Topics ETFs
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound. 
Via Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Don't overlook NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type 2 diabetes. Regulatory filings for Rybelsus expansion expected by 2025. 
Via Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in... 
Via Benzinga
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients with OUD and AUD, offering potential new treatments for addiction. 
Via Benzinga
'Miracle' Weight Loss Drug Ozempic And Similar Drugs Reduce Alcohol And Opioid Overdose, Study Reveals
Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing substance abuse. 
Via Benzinga
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run. 
Via The Motley Fool
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities. 
Via Benzinga
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors. 
Via The Motley Fool
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
Counterfeit and diverted weight loss drugs like Ozempic and Mounjaro are flooding international markets, posing serious health risks. Authorities are cracking down on illegal shipments as... 
Via Benzinga
Topics Law Enforcement
Exposures Legal
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the merger could harm competition in the GLP-1 market, potentially driving up... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.